BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 36.40
+0.90 (2.54%)
Mar 10, 2026, 11:04 AM CST
BioGend Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 | Upgrade
|
| Depreciation & Amortization | 49.77 | 51.19 | 55.02 | 53.18 | 28.19 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | -26.7 | Upgrade
|
| Loss (Gain) on Equity Investments | 1.84 | 2.46 | -10.34 | - | 11.35 | Upgrade
|
| Stock-Based Compensation | 6.16 | 3.64 | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.8 | - | - | - | - | Upgrade
|
| Other Operating Activities | -20.17 | -13.02 | -13.1 | -29.26 | -5.81 | Upgrade
|
| Change in Accounts Receivable | -12.4 | -20.67 | -15.42 | -6.22 | -4.72 | Upgrade
|
| Change in Inventory | -4.56 | 0.58 | -11.65 | 4.13 | 1.38 | Upgrade
|
| Change in Accounts Payable | -2.13 | 2.06 | 0.08 | 1.6 | -0.88 | Upgrade
|
| Change in Unearned Revenue | - | -2.5 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 1.64 | -16.17 | 13.02 | 2.23 | -1.12 | Upgrade
|
| Operating Cash Flow | -63.66 | -98.91 | -138.72 | -168.78 | -136.8 | Upgrade
|
| Capital Expenditures | -1.87 | -0.65 | -26.04 | -18.18 | -0.67 | Upgrade
|
| Cash Acquisitions | - | - | - | - | 26.41 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | 0.32 | - | - | Upgrade
|
| Investment in Securities | 100 | -6.24 | -64 | 223.2 | -159.97 | Upgrade
|
| Other Investing Activities | -31.71 | -1.31 | 0.08 | -3.32 | -0.04 | Upgrade
|
| Investing Cash Flow | 66.43 | -8.2 | -89.64 | 201.7 | -134.27 | Upgrade
|
| Long-Term Debt Repaid | -3.7 | -3.64 | -3.58 | -4.81 | -1.78 | Upgrade
|
| Net Debt Issued (Repaid) | -3.7 | -3.64 | -3.58 | -4.81 | -1.78 | Upgrade
|
| Issuance of Common Stock | - | - | 400 | - | 289.63 | Upgrade
|
| Financing Cash Flow | -3.7 | -3.64 | 396.42 | -4.81 | 287.85 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.2 | -0.74 | -1.19 | -0.79 | -0.49 | Upgrade
|
| Net Cash Flow | -1.12 | -111.49 | 166.87 | 27.32 | 16.28 | Upgrade
|
| Free Cash Flow | -65.52 | -99.56 | -164.76 | -186.96 | -137.47 | Upgrade
|
| Free Cash Flow Margin | -29.47% | -59.38% | -149.91% | -594.54% | -1483.13% | Upgrade
|
| Free Cash Flow Per Share | -0.53 | -0.81 | -1.37 | -1.81 | -1.36 | Upgrade
|
| Cash Interest Paid | 0.15 | 0.22 | 0.26 | 0.09 | 0.02 | Upgrade
|
| Cash Income Tax Paid | 0.42 | 0.5 | 0.2 | -0.18 | - | Upgrade
|
| Levered Free Cash Flow | -32.15 | -57.11 | -95.39 | -98.09 | -83.82 | Upgrade
|
| Unlevered Free Cash Flow | -32.05 | -56.97 | -95.23 | -98.04 | -83.81 | Upgrade
|
| Change in Working Capital | -17.44 | -26.7 | -13.97 | -8.25 | -5.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.